MARKET

BEAM

BEAM

BEAM THERAPEUTICS INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.73
-3.84
-12.56%
After Hours: 26.78 +0.05 +0.19% 19:53 07/10 EDT
OPEN
30.70
PREV CLOSE
30.57
HIGH
30.70
LOW
26.24
VOLUME
470.31K
TURNOVER
--
52 WEEK HIGH
31.80
52 WEEK LOW
13.00
MARKET CAP
1.38B
P/E (TTM)
-9.9895
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BEAM stock price target is 32.00 with a high estimate of 32.00 and a low estimate of 32.00.

EPS

BEAM News

More
Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies
Business Wire · 06/15 11:00
Magenta, Beam Therapeutics To Collaboration On Evaluation Of Targeted Antibody Drug Conjugate MGTA-117 As Conditioning Regimen For Base Editing Therapies
Magenta Therapeutics (NASDAQ:MGTA) and Beam Therapeutics (NASDAQ:BEAM) today announced a non-exclusive research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel
Benzinga · 06/15 10:03
Beam Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference
CAMBRIDGE, Mass., May 26, 2020 -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced.
GlobeNewswire · 05/26 10:30
Beam Therapeutics Taking Novel Approach to Gene Therapy
GuruFocus.com · 05/18 23:21
75 Biggest Movers From Yesterday
Gainers SIFCO Industries, Inc. (NYSE: SIF) shares climbed 88% to close at $4.14 on Wednesday following Q2 results. Sifco Industries posted Q2 earnings of $0.57 per share, versus a year-ago loss of $0.43 per share.
Benzinga · 05/14 08:26
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers SIFCO Industries, Inc. (NYSE: SIF) shares jumped 117% to $4.7799 following Q2 results. Sifco Industries posted Q2 earnings of $0.57 per share, versus a year-ago loss of $0.43 per share.
Benzinga · 05/13 16:41
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers SIFCO Industries, Inc. (NYSE: SIF) shares jumped 117% to $4.7799 following Q2 results. Sifco Industries posted Q2 earnings of $0.57 per share, versus a year-ago loss of $0.43 per share.
Benzinga · 05/13 16:41
Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering
Barrons.com · 05/12 18:40

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About BEAM

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines based on its base editing technology, to providing life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). It is advancing a broad, diversified portfolio of 12 base editing programs against distinct editing targets. Its programs are organized by delivery modality into three distinct pipelines: electroporation for delivery to blood cells and immune cells; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future; and adeno-associated viral vectors (AAV), for viral delivery to the eye and central nervous system (CNS).
More

Webull offers kinds of Beam Therapeutics Inc stock information, including NASDAQ:BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.